Luye Pharma Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015
Shanghai, April 20th, 2026 — Luye Pharma Group today announced that the first subject has been enrolled in a U.S. pharmacokinetic (PK) bridging clinical trial of its new molecular entity LY03015. This is the world’s first investigational drug designed to inhibit vesicular ...
April 20,2026
Luye Pharma Announces First Subject Enrolled in China Phase Ⅱ Clinical Trial of LY03017 (5-HT2AR/5-HT2CR) for Alzheimer’s ...
Shanghai, April 15th, 2026 — Luye Pharma Group today announced that the first subject has been enrolled in a Phase Ⅱ clinical trial in China to evaluate its LY03017 for the treatment of Alzheimer’s Disease-related Psychosis (ADP). Filed through China’s Class 1 pathway for ...
April 15,2026
08
2026-04
First Subject Enrolled in Phase Ⅱ Clinical Trial of Luye Pharma’s TAAR1/5-HT2CR-targeted Investigational Drug for Treating Schizophrenia
01
2026-04
Luye Pharma Announces 2025 Financial Results
13
2026-03
Luye Pharma Forms Strategic Partnership with Sinopharm Group and Sinopharm CNCM to Commercialize Mimeixin® and Other Products
08
2026-01
NMPA Accepts the NDA for Luye Pharma’s Ruoxinlin® for the New Indication of Generalized Anxiety Disorder
24
2025-12
Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Injectable Antipsychotics in the Chinese Mainland
07
2025-12
Luye Pharma’s Five New Products Included in China’s 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug List
24
2025-11
Luye Pharma Receives FDA Clearance of IND Application for Its Next-generation 5-HT2AR Inverse Agonist/5-HT2CR Antagonist LY03017
28
2025-08
Luye Pharma Announces 2025 Half-Year Results
18
2025-08
All Patients Enrolled for the Phase III Clinical Trial of Luye Pharma’s Ruoxinlin® for Treating Generalized Anxiety Disorder
03
2025-08
First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma’s Investigational Antidepressant Targeting NET/DAT/GABAAR
